Bill Reynolds

Vice President of Strategic Reimbursement

Bill has more than 40 years of experience in the field of medical technology (“medtech”) with a strategic focus on commercialization, reimbursement, and market access for medical devices, biologics, pharmaceuticals, molecular diagnostics, and related services. At Argenta, Bill is the leading voice in our strategic reimbursement team and a trusted strategic advisor to a broad range of executive teams. Bill coordinates a team of experienced consultants, certified coders, and medical directors to develop product-specific reimbursement landscape assessments and actionable long-term reimbursement strategies. In addition to a deep understanding of complex health economics and outcomes research (HEOR) factors, his experience gives him a broad practical understanding of the clinical, financial, economic, and human issues that can create focused reimbursement strategies and solve reimbursement challenges.

Bill regularly presents as a subject-matter expert on strategic issues impacting the commercialization of medical technologies and is an advisor to the startups at the Massachusetts Medical Device Development Center (M2D2) at the University of Massachusetts.

In his immediate past role he was with Conformis as Vice President, Market Access where he was responsible for developing and supporting the product value proposition strategy for payers and providers, direct payer coverage activity, value-added and risk-based contracting initiatives, and health economic study development and implementation for the only patient-specific, 3D-printed total knee and hip implants available worldwide.

Prior to that position Bill served as Vice President Reimbursement and Commercial Strategy for Mederi Therapeutics supporting the adoption of products utilizing thermal energy in the specialties of gastroenterology and colorectal surgery. Before joining Mederi he was with Olympus Corporation of the Americas as Executive Director, Reimbursement supporting adoption across all product lines and geographies as well as market assessment and evaluation of potential acquisition and/or in-license opportunities for targeted technologies and companies.

Before that he was with Transkaryotic Therapies (TKT) as Associate Director of Commercial Operations directing global reimbursement, pricing, distribution, and patient support functions for orphan drugs. Prior to joining TKT Bill served as Manager of Consulting for the Health Care Regulatory Group of PricewaterhouseCoopers. He also spent eight years with Genzyme Corporation, more recently as Program Manager directing reimbursement support for the launch of Carticel® with Genzyme Tissue Repair (now known as Genzyme Biosurgery) and previously as Manager of Reimbursement for the genetic testing laboratories currently known as Genzyme Genetics. He began his career with the Health Care Reimbursement Division of Blue Cross Blue Shield of Massachusetts and later spent two years as Director of Financial Planning at Choate-Symmes Hospital.

Bill received a Bachelor of Arts degree in economics from Westfield State University.